Paul F. Engstrom, MD, FACP, has been selected to receive the Lifetime Achievement Award in Cancer Prevention by the Prevention of Cancer Foundation. This award was presented at the Foundation’s 2018 Dialogue for Action Conference on April 12 in Tysons, Virginia.
Paul F. Engstrom, MD, FACP
Paul F. Engstrom, MD, FACP
Paul F. Engstrom, MD, FACP, has been selected to receive the Lifetime Achievement Award in Cancer Prevention by the Prevention of Cancer Foundation. This award was presented at the Foundation’s 2018 Dialogue for Action Conference on April 12 in Tysons, Virginia.
This award recognizes the many years Engstrom has dedicated to cancer prevention. He is known for establishing the first cancer prevention and control program at Fox Chase in 1979. He has also served as principal investigator for numerous cancer prevention and screening research programs.
One project Engstrom participated in focused on breast and ovarian cancer screening and diagnosis, known as the Early Detection Research Network. He is also recognized as one of the founding members of the National Comprehensive Cancer Network Patient Guideline Committee, and has been the spokesperson for national guidelines covering screening, diagnosis, management, and patient support.
Engstrom has worked at Fox Chase Cancer Center for over 45 years, with more than 50 years of experience as an oncologist. He currently serves as the vice president of population science at Fox Chase, having begun his career as a chairman for the department of medicine.
Engstrom also serves as chief of the section of general hematology/oncology, as well as a professor in the department of hematology/oncology. He is a special advisor to the president, as well as Samuel M.V. Hamilton Chair in Cancer Prevention.
“Dr. Engstrom is a true leader in cancer prevention, here at Fox Chase and around the world,” Richard I. Fisher, president and CEO at Fox Chase, said in a statement. “We congratulate him on receiving this lifetime achievement award and look forward to all that he will continue to accomplish.”
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen